HYBRID is a great opportunity to push the limits of medical imaging and merge the two most advanced imaging methods into a whole new modality.

Christophe Deroose, MD, PhD

Christophe M. Deroose is a nuclear medicine physician working at the University Hospitals Leuven. He is responsible for imaging and therapy in cancer management (pulmonary, gynecological and digestive). He is a  full professor at the KU Leuven since 2017. He is a Senior Clinical Investigator of the F.W.O-Flanders since 2016, with research focusing on optimizing the theranostic use of the somatostatin receptor.
 His research interest are focused on the use of nuclear medicine for diagnosis and therapy  in oncological patients. These applications include amongst others peptide receptor radionuclide therapy (PRRT) in patients with neuroendocrine tumors, assessment of response to treatment in oncological patients, improvements in dosimetry of patients treated with radionuclide therapy and tumor characterization for selection of treatment and prognostication. His preclinical research focuses on the development of reporter genes and genome editing strategies for insertion in stem cells.
He is the current vice-chair of the imaging group of the European Organisation for Research and Treatment of Cancer (EORTC). He is co-author of more than 90 peer-reviewed scientific publications and 7 book chapters in pre-clinical or clinical research.